Bak­er's dozen: Pfiz­er joins 12 peers in re­strict­ing sales of dis­count­ed drugs un­der a fed­er­al pro­gram

Be­gin­ning in March, Pfiz­er will be­come the 13th phar­ma com­pa­ny to re­strict sales of its drugs through a fed­er­al pro­gram that of­fers steep dis­counts for low-in­come in­di­vid­u­als.

The 340B pro­gram has come un­der fire as, ac­cord­ing to the phar­ma com­pa­nies, it has bal­looned in re­cent years to in­clude nu­mer­ous con­tract phar­ma­cies work­ing with cer­tain qual­i­fied hos­pi­tals. The hos­pi­tals, mean­while, have crit­i­cized the uni­lat­er­al moves by the phar­ma in­dus­try and have lost mil­lions in rev­enue from the changes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER